Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration: one year results from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS).
Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration: one year results from CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS).
复制标题
使用阿司匹林加低剂量噻氯匹定给药对西罗莫司洗脱冠状动脉支架植入的评估：CYPHER 支架日本上市后监测登记处 (J-PMS) 的一年结果。
DOI：
10.1253/circj.cj-08-0732
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
H. Yokoi
中科院分区：
文献类型：
--
作者：
Y. Ikari;J. Kotani;K. Kozuma;E. Kyo;Masato Nakamura;H. Yokoi
背景
西罗莫司洗脱支架（SES）植入的临床数据正在日本进行调查。
方法和结果
在50家医疗中心进行了CYPHER支架日本上市后监督登记研究（J-PMS），以评估仅在阿司匹林+低剂量噻氯匹定（200 mg/天）下的日常临床实践中的SES结果。2，054例患者的2，459处病变接受了3，285个SES治疗。平均年龄为67.1 ± 10.1岁，75.6%为男性，43.3%为糖尿病患者。77.2%的患者使用了血管内超声。8个月血管造影和1年临床随访数据分别为85.4%和96.8%。定量冠状动脉造影显示基线时参考血管直径和直径狭窄百分比分别为2.47 +/-0.58 mm和72.0 +/-16.1%。8个月晚期丢失为0.20 ± 0.50 mm。1年时的主要不良心血管事件为7.3%;心源性死亡：1.1%，心肌梗死（MI）：1.2%，靶病变血运重建（TLR）：4.2%。1年时明确和很可能支架内血栓形成的发生率分别为0.30%和0.10%。血液透析是死亡/MI或TLR的最强预测因子。
结论
J-PMS显示了在阿司匹林加低剂量噻氯匹定给药下1年时SES植入的有效性，但需要进一步研究来证明安全性。
BACKGROUND
Clinical data of sirolimus-eluting stent (SES) implantation are under investigation in Japan.
METHODS AND RESULTS
The CYPHER stent Japan Post-Marketing Surveillance Registry (J-PMS) was conducted at 50 medical centers to assess the results of SES in daily clinical practice exclusively under aspirin plus low dose ticlopidine (200 mg/day). A total of 2,459 lesions in 2,054 patients were treated with 3,285 SES. The mean age was 67.1 +/-10.1 years, 75.6% were men and 43.3% were diabetics. Intravascular ultrasound was used in 77.2%. The 8-month angiographic and 1-year clinical follow-up data were available in 85.4% and 96.8%, respectively. Quantitative coronary angiography showed the reference vessel diameter and percentage diameter stenosis at baseline were 2.47 +/-0.58 mm and 72.0 +/-16.1%. The 8-month late loss was 0.20 +/-0.50 mm. The major adverse cardiovascular events at 1 year was 7.3%; cardiac death: 1.1%, myocardial infarction (MI): 1.2%, and target lesion revascularization (TLR): 4.2%. The rates of definite and probable stent thrombosis at 1 year were 0.30% and 0.10%, respectively. Hemodialysis was the strongest predictor of death/MI or TLR.
CONCLUSIONS
J-PMS showed the effectiveness of SES implantation under aspirin plus low dose ticlopidine administration at 1 year, although further studies are necessary to demonstrate the safety.
使用药物洗脱支架进行经皮冠状动脉介入治疗的基于性别的结果（来自国家心、肺和血液研究所动态登记处）。
DOI：
10.1016/j.amjcard.2006.09.109
发表时间：
2007
期刊：
The American journal of cardiology
影响因子：
--
作者：
Abbott,JDawn;Vlachos,HelenA;Selzer,Faith;Sharaf,BarryL;Holper,Elizabeth;Glaser,Ruchira;Jacobs,AliceK;Williams,DavidO;NationalHeart,Lung,andBloodInstituteDynamicRegistry
通讯作者：
NationalHeart,Lung,andBloodInstituteDynamicRegistry